市场调查报告书
商品编码
1276796
角膜植入物全球市场规模、份额和行业趋势分析报告:按疾病类型、手术类型、最终用户、地区展望和预测,2023-2029 年Global Corneal Implants Market Size, Share & Industry Trends Analysis Report By Disease Type, By Procedure Type (Penetrating Keratoplasty, Endothelial Keratoplasty, and Others), By End User, By Regional Outlook and Forecast, 2023 - 2029 |
到 2029 年,角膜植入物的市场规模预计将达到 5.951 亿美元,预测期内復合年增长率为 6.4%。
眼睛的角膜执行几个重要的功能,例如保护眼睛的内部组织、辅助屈光力以及将光线以最小的散射和光学退化聚焦到视网膜上。需要角膜移植的疾病包括福赫氏营养不良、圆锥角膜、角膜炎、角膜溃疡、角膜瘢痕和角膜水肿,根据疾病的严重程度,可能需要进行角膜移植。
随着角膜问题的频繁发生,角膜植入物的市场正在扩大。新兴市场角膜失明率的增加和对角膜移植的需求也促进了市场扩张。角膜植入物市场的扩张预计将受到医疗保健支出和基础设施的增加、政府在医疗保健领域政策的转变、可支配收入的增加以及製药行业的发展的推动。
COVID-19 的影响分析
COVID-19 大流行破坏了角膜植入物市场。为了节省成本和降低感染风险,许多医院和诊所不得不推迟或取消角膜移植等非紧急手术,导致角膜植入物市场遭遇重大挫折。特别是在大流行的早期阶段,地方和国家当局严格的封锁规定限制了患者就诊以获得非必要护理。角膜移植术和视力恢復手术等眼科手术被归类为可以推迟的择期手术,进一步削弱了市场表现。
市场增长因素
角膜失明和其他视力损害疾病的病例增加
据估计,全世界有 1000 万人被诊断出患有双侧角膜失明,这使得角膜疾病成为导致失明的主要原因之一。角膜混浊占所有病例的 3.2%,使其成为全球最常见的失明原因之一。根据世界卫生组织 (WHO) 的一份新报告,包括 200 万沙眼患者在内的 600 万人患有角膜相关性失明或中度至重度视力障碍。近视或远视影响全球约 22 亿人。其中至少有 10 亿(约一半)是可预防的视力丧失病例,但尚未得到解决。
对人工角膜的需求不断增长
人工角膜可以克服眼表疾病、免疫排斥和免疫移植的风险。人造角膜不易膨胀,从而减少了光散射和积水。由于角膜失明的高发率和角膜供体的缺乏,预计角膜植入物製造商将有较大的增长速度。此外,由于角膜感染患病率的增加,预计人工角膜植入物将出现显着增长。因此,与传统角膜相比具有各种优势的人造角膜的出现有望促进角膜植入物市场的增长。这将推动市场增长。
市场製约因素
阻碍角膜植入物传播的问题
发展中国家的大多数医疗机构将角膜植入物视为门诊手术。因此,角膜植入物在这些地区并不是很受欢迎。在这些地区,如果没有足够的医疗基础设施,现有企业和新企业很难进入市场。近年来,随着有希望的替代方法的出现,角膜内环段移植的接受率持续下降。因此,建立角膜移植手术中心所需的高资金成本、供体短缺等预计将阻碍市场增长。
治疗类型的前景
根据手术类型,角膜植入物市场分为渗透性角膜移植术、内皮角膜移植术等。到 2022 年,内皮角膜移植术部分在角膜植入物市场中占据了重要的收入份额。这是因为最现代类型的角膜移植使用内皮角膜移植术,它仅替换受损组织,而不是角膜的整个厚度。由于感染机会和眼睛表面损伤较少等特点,该程序有助于更快更好地恢復视力。
病种展望
角膜植入物市场按疾病类型分为圆锥角膜、Fuch 营养不良、感染性角膜炎等。Fuchth 的营养不良部分代表了 2022 年角膜植入物市场的最大收入份额。这是由于人们对眼睛健康的瞭解越来越多,而 Fuchs 营养不良症越来越普遍。在 Fuchs 营养不良患者中,眼睛前部的透明层(角膜)变得充满液体,导致角膜肿胀和变厚。这会导致眩光、起雾或视力障碍,以及眼睛不适。
最终用户视角
按最终用户划分,角膜植入物市场分为医院、眼科中心等。2022 年,医院部门在角膜植入物市场的收入份额最高。这是由于高素质的医疗保健专业人员的可用性以及私人和团体保险计划中以医院为基础的医疗保健服务的覆盖范围不断扩大。医院也有专门的设备和设施,例如手术室、重症监护室和专科眼科手术室。因此,由于专家和高科技设备的存在来进行这些手术,预计在预测期间医院部门的增长将会增加。
区域展望
按地区划分,对北美、欧洲、亚太地区和 LAMEA 的角膜植入物市场进行了分析。北美地区将在 2022 年以最大的收入份额引领角膜植入物市场。在这种背景下,由于医疗保健基础设施的发展,角膜疾病的患病率有所增加。此外,人工角膜植入物的重要生产商数量激增以及公众对健康和福祉的认识不断提高,也有助于该地区的市场增长。此外,圆锥角膜的流行也有望增加角膜植入物的需求,这有望刺激北美市场的扩张。
The Global Corneal Implants Market size is expected to reach $595.1 Million by 2029, rising at a market growth of 6.4% CAGR during the forecast period.
Sometimes referred to as corneal inlays, corneal implants are optical devices placed into the cornea to improve eyesight. In addition to treating hyperopia, myopia, and astigmatism, the corneal implant technique is performed in cases of keratoconus and other degenerative disorders. Corneal implants are mostly used to treat presbyopia in adults by enhancing close vision and lowering the need for glasses.
A corneal transplant replaces the cornea with a donor or synthetic cornea. In this surgery, artificial or donor corneas are used to replace the cornea. The donor corneas used for transplantation are stored at eye banks in a storage medium. A synthetic cornea can also be chosen by transplant patients who can't accept a human donor cornea.
The cornea in the eye serves several crucial functions, including safeguarding interior eye tissues, assisting with refractive power, and focusing light on the retina with minimal possible scatter and optical degradation. Depending on their severity, certain disorders require corneal transplantation, including Fuchs dystrophy, keratoconus, keratitis, corneal ulcers, corneal scarring, and corneal edema.
The market for corneal implants is expanding as corneal problems are becoming more common. Also, the rise in corneal blindness in developing nations and the demand for corneal transplants contribute to the market's expansion. The expansion of the corneal implant market is anticipated to be fueled by an increase in healthcare spending and infrastructure, a shift in government policy in the healthcare sector, an increase in disposable income, and the development of the pharmaceutical industry.
COVID-19 Impact Analysis
The COVID-19 pandemic had a damaging effect on the Corneal Implant market. To save cost and lower the danger of infection, many hospitals and clinics had to postpone or cancel non-urgent procedures, such as corneal transplants, which caused a significant setback for the corneal implants market. Particularly during the early stages of the pandemic, patients' hospital trips for non-essential treatments were restricted by the severe lockdown regulations imposed by the local and national authorities. The classification of ophthalmic procedures, such as keratoplasty and sight-restoring surgeries, as elective surgical procedures that can be postponed further hindered the market's financial performance.
Market Growth Factors
Rising cases of corneal blindness and other vision impairment diseases
With an estimated 10 million patients diagnosed with bilateral corneal blindness globally, corneal disorders are one of the leading causes of blindness. At 3.2% of all cases, corneal opacity ranks amongst the world's most common causes of blindness. Six million people, including 2 million with trachoma, have cornea-related blindness or moderate to severe visual impairment, according to a new World Health Organization (WHO) report. Near- or distance vision impairment impacts approximately 2.2 billion people globally. At least 1 billion of these cases, roughly half involved vision impairment that could have been prevented or was not addressed.
The surging requirement for artificial cornea
The artificial cornea can overcome ocular surface disease, immunological rejection, and immune graft danger. The artificial cornea has reduced swellability, which means it will have less light scattering and water accumulation. A significant rate of growth is anticipated for corneal implant manufacturers due to the high prevalence of corneal blindness and the absence of corneal donors. Furthermore, the artificial cornea implant is anticipated to grow significantly due to the increasing prevalence of corneal infections. Thus, the presence of the artificial cornea with various benefits over the traditional one is expected to surge the corneal implant market growth. This will expedite the market's growth.
Market Restraining Factors
Issues restricting wider adoption of corneal implants
Most healthcare facilities in developing nations treat corneal implants as outpatient procedures. This has made corneal implants less popular in these parts of the world. If there isn't enough healthcare infrastructure in these areas, it would be hard for existing and new businesses to break into the market. Since promising alternatives have become available, the acceptance rate of intrastromal corneal ring segment implantation has been going down over the past few years. Thus, the need for high capital to establish surgery centers for cornea implants, lack of donors, and other factors are expected to hinder the market growth.
Procedure Type Outlook
Based on procedure type, the corneal implants market is segmented into penetrating keratoplasty, endothelial keratoplasty and others. The endothelial keratoplasty segment acquired a substantial revenue share in the corneal implants market in 2022. This is because the most recent kind of corneal transplant uses endothelial keratoplasty, which replaces only the damaged tissue rather than the entire thickness of the cornea. This procedure aids in quicker and better sight recovery due to its features like less possibilities of infection and eye surface injuries.
Disease Type Outlook
On the basis of disease type, the corneal implants market is divided into keratoconus, fuchs' dystrophy, infectious keratitis and others. The fuchs' dystrophy segment witnessed the largest revenue share in the corneal implants market in 2022. This is owing to the increased knowledge of ocular health and Fuchs' dystrophy being more common. The clear layer (cornea) on the front of the eye becomes clogged with fluid when a person has Fuchs' dystrophy, which causes the cornea to enlarge and thicken. As a result, glare, clouded or impaired vision, and eye discomfort may result.
End User Outlook
By end-user, the corneal implants market is classified into hospitals, ophthalmic centers and others. The hospitals segment registered the highest revenue share in the corneal implants market in 2022. This is due to the availability of highly qualified healthcare professionals and the expansion of private & group insurance plans' coverage of hospital-based healthcare services. Hospitals also have specialist equipment and facilities, such as operating rooms, intensive care units, and units for specialty eye surgery. Hence, with the presence of specialists and high-tech machinery to perform these surgeries, the hospital segment growth is expected to boost in the projected period.
Regional Outlook
Region-wise, the corneal implants market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the corneal implants market by generating the maximum revenue share in 2022. This is because of a rise in the infrastructure for healthcare and an increase in the prevalence of corneal illnesses. Also, a surge in the number of significant producers of artificial corneal implants and a rise in public awareness of health and well-being contribute to the market growth in this area. Furthermore, the prevalence of keratoconus is also anticipated to enhance demand for corneal implants, which is anticipated to spur market expansion in North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Presbia PLC, CorNeat Vision Ltd., Alcon, Inc., AJL Opthalmic SA, LinkoCare Life Sciences AB, CorneaGen, DIOPTEX GmbH, Mediphacos Industrias Medicas S.A., EyeYon Medical Ltd., and KeraMed, Inc.
Strategies Deployed in Corneal implants Market
Nov-2022: Alcon took over Aerie Pharmaceuticals, a US-based clinical-stage pharmaceutical company. The addition of Aerie expands Alcon's market presence in the ophthalmic pharmaceutical market. Moreover, Aerie's deep technical expertise supports the company's endeavor to develop a comprehensive portfolio of ophthalmic pharmaceuticals.
Apr-2022: CorneaGen introduced EndoSerter-PL, an FDA-approved insertion device. The single-use graft insertion device is equipped with masterly processed tissue to smoothen the DSEK surgeries.
Jan-2022: Alcon took over Ivantis, a US-based manufacturer of surgical devices for the treatment of eye diseases. The acquisition brings in Ivantis' Hydrus Microstent, which would be added to the acquiring company's global portfolio. Further, the addition of Ivantis reinforces Alcon's global surgical portfolio.
Jan-2022: CorneaGen signed an agreement with MellingMedical, a provider of pharmaceuticals, surgical, wound care, and etc. products. The agreement involves Melling providing Federal Health facilities with CorneaGen tissue. The partnership broadens CorneaGen's devotion to transforming the lives of people with corneal diseases, particularly America's veterans.
Jun-2021: EyeYon Medical for its EndoArt received CE Mark. EndoArt is a synthetic implant, which takes place of human endothelium that a body cannot regenerate. This approval enables the company to work in close relations with the healthcare providers to make patients live a better quality of life.
Mar-2021: CorNeat Vision came into partnership with LiveU and Alcon, a US-based provider of live video streaming services. Alcon is a US-based Ophthalmology company. The partnership focuses on implementing a remote surgeon virtual presence (RSVP) solution. The partnership involves cashing on Alcon's NGENUITY 3D Visualization System to carry out remote training of cornea experts located in Toronto. The partnership further boosts CorNeat's CorNeat KPro sales, as it would allow the company to train physicians across the world without physical presence.
Mar-2019: Alcon completed the acquisition of PowerVision, a US-based developer of implantable intraocular lenses. The acquisition reflects Alcon's devotion to driving forward the growth and innovation in AT-IOLS, advanced technology intraocular lenses.
Feb-2019: CorneaGen took over KeraLink Domestic Eye Bank Operations, a US-based provider of eye bank services. The acquisition broadens the company's surgical product offerings. Further, the addition of KeraLink Domestic Eye Bank Operations also brings in partnerships with industry and research communities which would further enhance the acquiring company's access to major and important discoveries in corneal disease treatment.
Market Segments covered in the Report:
By Disease Type
By Procedure Type
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures